News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Advances Game-Changing Pain and Inflammation Therapy

January 24, 2019

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Read More

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

January 6, 2019

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

 

Read More

Veristat Partners with TRI For Risk-Based Monitoring Technology

November 5, 2018

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

 

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

August 15, 2018

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval

 

SOUTHBOROUGH, MA –  August 15, 2018 –   Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. 

Read More

Veristat Congratulates TESARO on the FDA Approval of ZEJULA™

May 30, 2017

SOUTHBOROUGH, MA –  May 30, 2017 –   Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval of ZEJULA™.  

Read More

Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive Year

May 15, 2017

Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts

Read More

Veristat Appoints James Roach, MD as Chief Medical Officer

November 7, 2016

Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings


SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
Read More

Veristat Formalizes its Strategic Decision Consulting Services

November 1, 2016

SOUTHBOROUGH, MA –  November 01, 2016Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.  

Read More